“He is talking about bringing growth and investment. Last week, he lost a £450m investment from AstraZeneca that we ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, innovative ...

Harvey Jones called on artificial intelligence to help him decide where to invest this year's Stocks and Shares ISA allowance ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Cancer remains one of the leading causes of death globally, with delayed diagnoses and limited access to advanced care significantly contributing to poor outcomes.

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

AstraZeneca has retracted a planned £450 million investment in Britain, citing reduced government support as a key factor.

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult pat ...